Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Select Advanced Malignancies Clear all
Active, not recruiting Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions
BEZ235 + MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced May 21, 2026, 11:06 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions
STK-012, pembrolizumab, pemetrexed, carboplatin
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 11:06 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
33
States / cities
Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer, Multiple Indications
Interventions
Anti-PDL-1 antibody
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced May 21, 2026, 11:06 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-2
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
Interventions
MEDI0680, Durvalumab, Nivolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Tampa, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced May 21, 2026, 11:06 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, PD-L1 Negative
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
130
States / cities
Tucson, Arizona • Burbank, California • La Jolla, California + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 11:06 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced May 21, 2026, 11:06 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601, Gemcitabine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
MEDI6383, MEDI6383 and MEDI4736
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced May 21, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
DB-1317
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 11:06 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions
AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 21, 2026, 11:06 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
BI 770371, ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Sarasota, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced May 21, 2026, 11:06 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BG-C0979, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced May 21, 2026, 11:06 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Interventions
Naporafenib, Dacarbazine, Temozolomide, Trametinib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • San Francisco, California • Englewood, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Veliparib
Other · Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced May 21, 2026, 11:06 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions
CM-24 (MK-6018), Pembrolizumab (MK-3475)
Biological
Lead sponsor
Famewave Ltd.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor
Interventions
Sym021, Sym022, Sym023, Irinotecan Hydrochloride
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer
Interventions
AGEN1884 + AGEN2034
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced May 21, 2026, 11:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions
BYL719, AMG 479
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced May 21, 2026, 11:06 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 11:06 PM EDT